Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “hyaluronidase” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 12
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 12 pipeline programs matching "hyaluronidase" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

12 results for “hyaluronidase” Back to intelligence hub

Search results

  1. Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial
  2. Hyaluronidase

    Amphastar France Pharmaceuticals

    Allergic Skin Reaction

    phase 2 small molecule completed

    1 trial
  3. Pegvorhyaluronidase alfa

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial
  4. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial
  5. Recombinant human hyaluronidase + immune globulin intravenous

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 mab completed

    1 trial
  6. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial
  7. Recombinant human hyaluronidase PH20 (rHuPH20)

    HALOZYME THERAPEUTICS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial
  8. Commercial Hylenex® recombinant (hyaluronidase human injection)

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial
  9. Isotonic hydration fluid and recombinant human hyaluronidase

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule terminated

    1 trial
  10. hyaluronidase (human recombinant)/rehydration fluid

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule completed

    1 trial
  11. recombinant human hyaluronidase

    HALOZYME THERAPEUTICS, INC.

    Healthy

    approved small molecule completed

    1 trial
  12. recombinant human hyaluronidase

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.